How do aCGH and SNV microarrays compare for CNV diagnostic testing? Key Differences & Clinical Selection Guide

Here’s the core difference: oligonucleotide aCGH detects copy number changes by comparing a patient’s DNA to a normal reference, while SNV arrays measure allele intensities directly without a reference. For diagnostic CNV testing, this means aCGH excels at identifying gains and losses but is blind to copy-number-neutral events. SNV arrays provide the same copy number data plus the ability to detect loss of heterozygosity, uniparental disomy, and long contiguous stretches of homozygosity — abnormalities aCGH cannot resolve. The choice hinges on whether detecting these “silent” chromosomal rearrangements matters for your diagnostic panel.

While oligonucleotide aCGH and SNV microarrays both deliver high-resolution genome-wide CNV analysis, they operate on fundamentally different signal-generation principles. aCGH uses a comparative, dual-dye approach that requires a matched reference sample, whereas SNV arrays directly genotype and measure allele intensity. The critical diagnostic advantage of SNV arrays is their ability to reveal copy-number-neutral events like loss of heterozygosity, which aCGH is structurally unable to detect.

Understanding the Core Technical Divergence

These two platforms may look similar as microarrays, but how they measure copy number shapes their diagnostic strengths and blind spots. The distinction goes far deeper than sample preparation — it fundamentally defines what clinical information you can report.

The aCGH Signal: A Relative, Comparative Measurement

Oligonucleotide aCGH measures gene dosage as a ratio. Patient DNA labeled with one fluorophore (e.g., Cy5) and a normal reference DNA labeled with another (Cy3) compete for hybridization to array probes. The fluorescent ratio at each probe spot reveals whether the patient has a gain, loss, or normal copy number relative to that reference. This comparative design means the reference sample’s own copy number profile — including any undetected variants — becomes part of the measurement.

This relative nature is both an elegant normalization strategy and a fundamental limitation. It cancels out many technical noise sources, but it also erases information about allele origin and copy-number-neutral states. If a patient has two identical copies of a region from one parent (uniparental disomy), the signal ratio stays balanced, and the abnormality remains invisible.

The SNV Array Signal: An Absolute, Genotype-Informed Measurement

SNV arrays take a different approach entirely. Each probe interrogates a specific single nucleotide polymorphism, and the array directly measures the intensity of the two possible allele signals. No reference sample is co-hybridized. Instead, the array captures both total signal intensity (revealing copy number) and the ratio of allele A to allele B (revealing heterozygosity). This dual-channel information allows the algorithm to distinguish a normal diploid heterozygous state from a homozygous deletion or duplication, and critically, to identify regions of copy-number-neutral loss of heterozygosity. The result is a richer, genotype-level view of the genome.

Practical Implications for Diagnostic Testing

These technical differences translate into real-world consequences for test design, validation, and clinical utility. Diagnostic laboratories must weigh the information content against the operational complexity.

Detecting What aCGH Misses: The Value of Genotype Data

SNV arrays uniquely detect absence of heterozygosity. In prenatal and constitutional genetic testing, a large region of homozygosity can point to uniparental disomy, which may be associated with imprinting disorders. In cancer, acquired copy-neutral LOH is a common mechanism for inactivating tumor suppressor genes. If your diagnostic panel must report these findings, aCGH is insufficient — you would need an orthogonal method like methylation analysis or microsatellite analysis. SNV arrays consolidate both copy number and allelic information into a single assay.

Workflow and Quality Control Considerations

aCGH requires a matched normal reference DNA of known quality, introducing a potential source of pre-analytical variation. This reference must be handled, labeled, and stored alongside patient specimens. SNV arrays eliminate reference DNA dependency, simplifying the wet-bench portion of the assay and reducing one source of batch-to-batch variability. However, SNV array analysis software must accurately call genotypes and normalize across samples using internal controls or in-silico reference clusters, which adds analytical chain complexity. For high-throughput labs, the reduced hands-on time of a reference-free workflow can be a meaningful operational advantage.

Resolution and Probe Placement

Both technologies can achieve high resolution with densely tiled probes. Oligonucleotide aCGH platforms often use long 60-mer probes designed specifically for unique genomic regions, which can be optimized to avoid repetitive sequences that confound copy number calls. SNV arrays are constrained to locations where informative SNPs exist, though modern designs use both polymorphic and non-polymorphic copy number probes to fill genomic gaps. The practical resolution difference for diagnostic CNV detection is now minimal for most clinical applications, but for ultra-fine mapping of a specific region, custom aCGH designs can provide probe placement flexibility that fixed-content SNV arrays cannot match.

Understanding the Trade-offs

No platform is universally superior. The right choice depends entirely on the clinical questions your test must answer and the operational environment in which it runs.

• aCGH’s relative measurement provides inherent noise reduction but sacrifices any signal that does not alter net copy number. You cannot detect ploidy changes that keep the relative dosage constant (e.g., triploidy may appear normal) without additional analysis.
• SNV arrays offer richer data but require more complex bioinformatics pipelines. Allele-specific analyses must account for baseline shifts and cluster separation, which can degrade with low-quality or degraded DNA samples.
• SNV arrays are limited to known SNP positions, while aCGH can probe any unique sequence. For rare disease testing where breakpoint mapping requires custom probe design, aCGH retains a design flexibility advantage.
• Cost and reagent simplicity can favor aCGH in certain settings, as dual-label kits are well-established. However, eliminating the reference sample may reduce per-sample costs for SNV arrays in large batch runs, depending on the commercial platform.

Making the Right Choice for Your Diagnostic Goal

Your decision should align with the diagnostic yield you require and the operational constraints of your laboratory. Focus on the clinical information you cannot afford to miss.

• If your primary focus is purely copy number gains and losses in constitutional disorders: Oligonucleotide aCGH remains a robust, well-validated choice with straightforward data interpretation and flexible custom probe design.
• If your primary focus is detecting copy-number-neutral events like uniparental disomy or absence of heterozygosity: SNV microarrays are the clear technical necessity; aCGH is structurally blind to these clinically significant findings.
• If your primary focus is cancer genomics where copy-neutral LOH is a common tumor suppressor inactivation mechanism: SNV arrays provide the integrated copy number and genotype view needed to identify these events without reflex testing.
• If your primary focus is operational simplicity and reducing pre-analytical variables: The reference-free workflow of SNV arrays can streamline laboratory processes, though you must invest in robust bioinformatics validation.

Choosing between these platforms is about matching the technology’s fundamental signal to the clinical question at hand. By understanding that aCGH hears only relative dosage while SNV arrays listen for both dose and allele origin, you can align your diagnostic testing strategy with the outcomes that matter most for your patients.

Summary Table:

Optimizing your molecular diagnostic pipeline or developing high-performance genomic assays? CamelBio provides diagnostic manufacturers, clinical labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and expert consulting—supporting every stage from concept to clinic. Contact us today to elevate your assay performance and accelerate your diagnostic workflow!